DOXORUBICIN HYDROCHLORIDE injectable, liposomal

Doxorubicin Hydrochloride by

Drug Labeling and Warnings

Doxorubicin Hydrochloride by is a Prescription medication manufactured, distributed, or labeled by BluePoint Laboratories, Dr. Reddy’s Laboratories Limited, Natco Pharma Ltd. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS

    • Doxorubicin hydrochloride can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m2 to 550 mg/m2. Assess left ventricular cardiac function prior to initiation of doxorubicin hydrochloride liposome injection and during treatment, and after treatment (5.1)
    • Serios, life-threatening, and fatal infusion-related reactions can occur with doxorubicin hydrochloride liposome injection. Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold doxorubicin hydrochloride for infusion-related reactions and resume at a reduced rate. Discontinue doxorubicin hydrochloride liposome injection infusion for serious or life-threatening infusion-related reactions (5.2)].
  • 1 INDICATIONS AND USAGE

    1.1 Ovarian Cancer

    Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

    1.2 AIDS-Related Kaposi’s Sarcoma

    Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

    1.3 Multiple Myeloma

    Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Use Information

    Do not substitute doxorubicin hydrochloride liposome injection for other doxorubicin hydrochloride products.

    Do not administer as an undiluted suspension or as an intravenous bolus [see Warnings and Precautions (5.2)].

    2.2 Ovarian Cancer

    The recommended dose of doxorubicin hydrochloride liposome injection is 50 mg/m2 intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity.

    2.3 AIDS-Related Kaposi’s Sarcoma

    The recommended dose of doxorubicin hydrochloride liposome injection is 20 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.

    2.4 Multiple Myeloma

    The recommended dose of doxorubicin hydrochloride liposome injection is 30 mg/m2 intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer doxorubicin hydrochloride liposome injection after bortezomib on day 4 of each cycle [see Clinical Studies (14.3)].

    2.5 Dose Modifications for Adverse Reactions

    Do not increase doxorubicin hydrochloride liposome injection after a dose reduction for toxicity. 

    Table 1: Recommended Dose Modifications for Hand-Foot Syndrome, Stomatitis, or Hematologic Adverse Reactions 

    Toxicity

    Dose Adjustment

    Hand-Foot Syndrome (HFS)

    Grade 1: Mild erythema, swelling, or desquamation not interfering with daily activities

    If no previous Grade 3 or 4 HFS: no dose adjustment.
    If previous Grade 3 or 4 HFS: delay dose up to 2 weeks, then decrease dose by 25%.

    Grade 2: Erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter

    Delay dosing up to 2 weeks or until resolved to Grade 0-1.
    Discontinue doxorubicin hydrochloride liposome injection if no resolution after 2 weeks.
    If resolved to Grade 0-1 within 2 weeks:
    o And no previous Grade 3 or 4 HFS: continue treatment at  previous dose.
    o And previous Grade 3 or 4 toxicity: decrease dose by 25%.

    Grade 3: Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing

    Delay dosing up to 2 weeks or until resolved to Grade 0-1, then decrease dose by 25%.
    Discontinue doxorubicin hydrochloride liposome injection if no resolution after 2 weeks.

    Grade 4: Diffuse or local process causing infectious complications, or a bed ridden state or hospitalization

    Delay dosing up to 2 weeks or until resolved to Grade 0-1, then decrease dose by 25%.
    Discontinue doxorubicin hydrochloride liposome injection if no resolution after 2 weeks.

    Stomatitis

    Grade 1: Painless ulcers, erythema, or mild soreness

    If no previous Grade 3 or 4 toxicity: no dose adjustment.

    If previous Grade 3 or 4 toxicity: delay up to 2 weeks then decrease dose by 25%.

    Grade 2: Painful erythema, edema, or ulcers, but can eat

    Delay dosing up to 2 weeks or until resolved to Grade 0-1.
    Discontinue doxorubicin hydrochloride liposome injection if there is no resolution after 2 weeks.
    If resolved to Grade 0-1 within 2 weeks:
    o And no previous Grade 3 or 4 stomatitis: resume treatment at previous dose.
    o And previous Grade 3 or 4 toxicity: decrease dose by 25%.

    Grade 3: Painful erythema, edema, or ulcers, and cannot eat

    Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval.
    If after 2 weeks there is no resolution, discontinue doxorubicin hydrochloride liposome injection.

    Grade 4: Requires parenteral or enteral support

    Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval.

    If after 2 weeks there is no resolution, discontinue doxorubicin hydrochloride liposome injection.

    Neutropenia or Thrombocytopenia

    Grade 1

    No dose reduction

    Grade 2

    Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose

    Grade 3

    Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous dose

    Grade 4

    Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume at 25% dose reduction or continue previous dose with prophylactic granulocyte growth factor

    Table 2: Recommended Dose Modifications of Doxorubicin Hydrochloride Liposome Injection for Toxicity When Administered in Combination With Bortezomib

    Toxicity

    Doxorubicin Hydrochloride Liposome Injection

    Fever ≥38°C and ANC <1,000/mm3 

    Withhold dose for this cycle if before Day 4;

    Decrease dose by 25%, if after Day 4 of previous cycle.

    On any day of drug administration after Day 1 of each cycle:
    Platelet count <25,000/mm3
      Hemoglobin <8 g/dL
    ANC <500/mm3 

    Withhold dose for this cycle if before Day 4;

    Decrease dose by 25%, if after Day 4 of previous cycle AND if bortezomib is reduced for hematologic toxicity.

    Grade 3 or 4 non-hematologic drug related toxicity

    Do not dose until recovered to Grade <2, then reduce dose by 25%.

    For neuropathic pain or peripheral neuropathy, no dosage adjustments are required for doxorubicin hydrochloride liposome injection. Refer to bortezomib manufacturer’s prescribing information.

    2.6 Preparation and Administration

    Preparation

    Dilute doxorubicin hydrochloride liposome injection doses up to 90 mg in 250 mL of 5% Dextrose Injection, USP prior to administration. Dilute doses exceeding 90 mg in 500 mL of 5% Dextrose Injection, USP prior to administration. Refrigerate diluted doxorubicin hydrochloride liposome injection at 2°C to 8°C (36°F to 46°F) and administer within 24 hours.  

    Administration

    Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present.  

    Do not use with in-line filters.

    Administer the first dose of doxorubicin hydrochloride liposome injection at an initial rate of 1 mg/min. If no infusion-related adverse reactions are observed, increase the infusion rate to complete the administration of the drug over one hour [see Warnings and Precautions (5.2)].

    Do not rapidly flush the infusion line.  Do not mix doxorubicin hydrochloride liposome injection with other drugs.

    Management of Suspected Extravasation

    Discontinue doxorubicin hydrochloride liposome injection for burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation. Manage confirmed or suspected extravasation as follows:

    Do not remove the needle until attempts are made to aspirate extravasated fluid

    Do not flush the line

    Avoid applying pressure to the site

    Apply ice to the site intermittently for 15 min 4 times a day for 3 days

    If the extravasation is in an extremity, elevate the extremity  

    2.7 Procedure for Proper Handling and Disposal

    Doxorubicin hydrochloride liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 If doxorubicin hydrochloride liposome injection comes into contact with skin or mucosa, immediately wash thoroughly with soap and water.

  • 3 DOSAGE FORMS AND STRENGTHS

    Doxorubicin hydrochloride liposome injection: 20 mg/10 mL (2mg/mL) and 50 mg/25 mL (2mg/mL) in single-dose vials. The drug product appears as a translucent, red liposomal dispersion. 

  • 4 CONTRAINDICATIONS

    Doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Cardiomyopathy

    Doxorubicin hydrochloride can result in myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy with doxorubicin hydrochloride is generally proportional to the cumulative exposure. Include prior use of other anthracyclines or anthracenediones in calculations of cumulative dose. The risk of cardiomyopathy may be increased at lower cumulative doses inpatients with prior mediastinal irradiation.

    In a clinical study in 250 patients with advanced cancer who were treated with doxorubicin hydrochloride liposome injection, the risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 to 550 mg/m2. Cardiomyopathy was defined as >20% decrease in resting left ventricular ejection fraction (LVEF) from baseline where LVEF remained in the normal range or a >10% decrease in LVEF from baseline where LVEF was less than the institutional lower limit of normal. Two percent of patients developed signs and symptoms of congestive heart failure without documented evidence of cardiomyopathy.  

    Assess left ventricular cardiac function (e.g. MUGA or echocardiogram) prior to initiation of doxorubicin hydrochloride liposome injection, during treatment to detect acute changes, and after treatment to detect delayed cardiomyopathy. Administer doxorubicin hydrochloride liposome injection to patients with a history of cardiovascular disease only when the potential benefit of treatment outweighs the risk.

    5.2 Infusion-Related Reactions

    Serious, life-threatening, and fatal infusion-related reactions characterized by one or more of the following symptoms can occur with doxorubicin hydrochloride liposome injection: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. Of 239 patients with ovarian cancer treated with doxorubicin hydrochloride liposome injection in Trial 4, 7% of patients experienced acute infusion-related reactions resulting in dose interruption. All occurred during cycle 1 and none during subsequent cycles. Across multiple studies of doxorubicin hydrochloride liposome injection monotherapy including this and other studies enrolling 760 patients with various solid tumors, 11% of patients had infusion-related reactions. The majority of infusion-related events occurred during the first infusion.

    Ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of doxorubicin hydrochloride liposome injection. Initiate doxorubicin hydrochloride liposome injection infusions at a rate of 1 mg/min and increase rate as tolerated [see Dosage and Administration (2.6)]. Withhold doxorubicin hydrochloride liposome injection for Grade 1, 2, or 3 infusion-related actions and resume at a reduced infusion rate. Discontinue doxorubicin hydrochloride liposome injection infusion for serious or life-threatening infusion-related reactions.

    5.3 Hand-Foot Syndrome (HFS)

    In Trial 4, the incidence of HFS was 51% of patients in the doxorubicin hydrochloride liposome injection arm and 0.9% of patients in the topotecan arm, including 24% Grade 3 or 4 cases of HFS in doxorubicin hydrochloride liposome injection-treated patients and no Grade 3 or 4 cases in topotecan-treated patients. HFS or other skin toxicity required discontinuation of doxorubicin hydrochloride liposome injection in 4.2% of patients.  

    HFS was generally observed after 2 or 3 cycles of treatment but may occur earlier. Delay doxorubicin hydrochloride liposome injection for the first episode of Grade 2 or greater HFS [see Dosage and Administration (2.5)]. Discontinue doxorubicin hydrochloride liposome injection if HFS is severe and debilitating.

    5.4 Secondary Oral Neoplasms

    Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post-marketing experience in patients with long-term (more than one year) exposure to doxorubicin hydrochloride liposome injection. These malignancies were diagnosed both during treatment with doxorubicin hydrochloride liposome injection and up to 6 years after the last dose. Examine patients at regular intervals for the presence of oral ulceration or with any oral discomfort that may be indicative of secondary oral cancer.

    The altered pharmacokinetics and preferential tissue distribution of liposomal doxorubicin that contributes to enhanced skin toxicity and mucositis compared to free doxorubicin may play a role in the development of oral secondary malignancies with long-term use.

    5.5 Embryo-Fetal Toxicity

    Based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the use of doxorubicin hydrochloride liposome injection during the 1st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2nd and 3rd trimesters. At doses approximately 0.12 times the recommended clinical dose, doxorubicin hydrochloride liposome injection was embryotoxic and abortifacient in rabbits. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and for 6 months after treatment with doxorubicin hydrochloride liposome injection [see Use in Specific Populations (8.1) and (8.3)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in more detail in other sections of the labeling.

    Cardiomyopathy [see Warnings and Precautions (5.1)]

    Infusion-Related Reactions [see Warnings and Precautions (5.2)]

    Hand-Foot Syndrome [see Warnings and Precautions (5.3)]

    Secondary Oral Neoplasms [see Warnings and Precautions (5.4)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice.  

    The safety data reflect exposure to doxorubicin hydrochloride liposome injection in 1310 patients including: 239 patients with ovarian cancer, 753 patients with AIDS-related Kaposi’s sarcoma, and 318 patients with multiple myeloma.

    The most common adverse reactions (>20%) observed with doxorubicin hydrochloride liposome injection are asthenia, fatigue, fever, nausea, stomatitis, vomiting, diarrhea, constipation, anorexia, hand-foot syndrome, rash and neutropenia, thrombocytopenia and anemia.

    The following tables present adverse reactions from clinical trials of single-agent doxorubicin hydrochloride liposome injection in ovarian cancer and AIDS-Related Kaposi’s sarcoma.

    Patients With Ovarian Cancer

    The safety data described below are from Trial 4, which included 239 patients with ovarian cancer treated with doxorubicin hydrochloride liposome injection 50 mg/m2 once every 4 weeks for a minimum of four courses in a randomized, multicenter, open-label study. In this trial, patients received doxorubicin hydrochloride liposome injection for a median number of 3.2 months (range 1 day to 25.8 months). The median age of the patients is 60 years (range 27 to 87), with 91% Caucasian, 6% Black, and 3% Hispanic or Other. Table 3 presents the hematologic adverse reactions from Trial 4.

    Table 3: Hematologic Adverse Reactions in Trial 4

     

    Doxorubicin Hydrochloride Liposome Injection
    Patients
    (n=239)

    Topotecan Patients
    (n=235)

    Neutropenia

    500 -<1000/mm3  

     

    8%

     

    14%

    <500/mm3

    4.2%

    62%

    Anemia

    6.5 -<8 g/dL

     

    5%

     

    25%

    < 6.5 g/dL

    0.4%

    4.3%

    Thrombocytopenia

    10,000 -<50,000/mm3

     

    1.3%

     

    17%

    <10,000/mm3

    0%

    17%

    Table 4 presents the non-hematologic adverse reactions from Trial 4. 

    Table 4: Non-Hematologic Adverse Reactions in Trial 4

    Non-Hematologic Adverse Reaction 10% or GreaterDoxorubicin Hydrochloride Liposome Injection
    (%) treated
    (n=239)    		Topotecan (%) treated
    (n=235)
    All gradesGrades 3–4All gradesGrades 3–4

    Body as a Whole

    Asthenia

    40

    7

    52

    8

    Fever

    21

    0.8

    31

    6

    Mucous Membrane Disorder

    14

    3.8

    3.4

    0

    Back Pain

    12

    1.7

    10

    0.9

    Infection

    12

    2.1

    6

    0.9

    Headache

    11

    0.8

    15

    0

    Digestive

    Nausea

    46

    5

    63

    8

    Stomatitis

    41

    8

    15

    0.4

    Vomiting

    33

    8

    44

    10

    Diarrhea

    21

    2.5

    35

    4.2

    Anorexia

    20

    2.5

    22

    1.3

    Dyspepsia

    12

    0.8

    14

    0

    Nervous

    Dizziness

    4.2

    0

    10

    0

    Respiratory

    Pharyngitis

    16

    0

    18

    0.4

    Dyspnea

    15

    4.1

    23

    4.3

    Cough increased

    10

    0

    12

    0

    Skin and Appendages

    Hand-foot syndrome

    51

    24

    0.9

    0

    Rash

    29

    4.2

    12

    0.4

    Alopecia

    19

    N/A

    52

    N/A

    The following additional adverse reactions were observed in patients with ovarian cancer with doses administered every four weeks (Trial 4). 

    Incidence 1% to 10%

    Cardiovascular: vasodilation, tachycardia, deep vein thrombosis, hypotension, cardiac arrest.

    Digestive: oral moniliasis, mouth ulceration, esophagitis, dysphagia, rectal bleeding, ileus.

    Hematologic and Lymphatic: ecchymosis.  

    Metabolic and Nutritional: dehydration, weight loss, hyperbilirubinemia, hypokalemia, hypercalcemia, hyponatremia.  

    Nervous: somnolence, dizziness, depression.  

    Respiratory: rhinitis, pneumonia, sinusitis, epistaxis.  

    Skin and Appendages: pruritus, skin discoloration, vesiculobullous rash, maculopapular rash, exfoliative dermatitis, herpes zoster, dry skin, herpes simplex, fungal dermatitis, furunculosis, acne.  

    Special Senses: conjunctivitis, taste perversion, dry eyes.

    Urinary: urinary tract infection, hematuria, vaginal moniliasis.  

    Patients With AIDS-Related Kaposi’s Sarcoma

    The safety data described is based on the experience reported in 753 patients with AIDS-related Kaposi’s sarcoma (KS) enrolled in four open-label, uncontrolled trials of doxorubicin hydrochloride liposome injection administered at doses ranging from 10 to 40 mg/m2 every 2 to 3 weeks. Demographics of the population were: median age 38.7 years (range 24 to 70); 99% male; 88% Caucasian, 6% Hispanic, 4% Black, and 2% Asian/other/unknown. The majority of patients were treated with 20 mg/m2 of doxorubicin hydrochloride liposome injection every 2 to 3 weeks with a median exposure of 4.2 months (range 1 day to 26.6 months). The median cumulative dose was 120 mg/m2 (range 3.3 to 798.6 mg/m2); 3% received cumulative doses of greater than 450 mg/m2.  

    Disease characteristics were: 61% poor risk for KS tumor burden, 91% poor risk for immune system, and 47% poor risk for systemic illness; 36% were poor risk for all three categories; median CD4 count 21 cells/mm3 (51% less than 50 cells/mm3); mean absolute neutrophil count at study entry approximately 3,000 cells/mm3 .

    Of the 693 patients with concomitant medication information, 59% were on one or more antiretroviral medications [35% zidovudine (AZT), 21% didanosine (ddI), 16% zalcitabine (ddC), and 10% stavudine (D4T)]; 85% received PCP prophylaxis (54% sulfamethoxazole/trimethoprim); 85% received antifungal medications (76% fluconazole); 72% received antivirals (56% acyclovir, 29% ganciclovir, and 16% foscarnet) and 48% patients received colony-stimulating factors (sargramostim/filgrastim) during their course of treatment.

    Adverse reactions led to discontinuation of treatment in 5% of patients with AIDS-related Kaposi’s sarcoma and included myelosuppression, cardiac adverse reactions, infusion-related reactions, toxoplasmosis, HFS, pneumonia, cough/dyspnea, fatigue, optic neuritis, progression of a non-KS tumor, allergy to penicillin, and unspecified reasons. Tables 5 and 6 summarize adverse reactions reported in patients treated with doxorubicin hydrochloride liposome injection for AIDS-related Kaposi’s sarcoma in a pooled analysis of the four trials.

    Table 5: Hematologic Adverse Reactions Reported in Patients With AIDS-Related Kaposi’s Sarcoma

    Patients With Refractory or Intolerant
    AIDS-Related Kaposi's Sarcoma (n=74*)    		Total Patients With AIDS-Related
    Kaposi's Sarcoma (n=720**)
    *This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.
    **This includes only subjects with AIDS-KS who had available data from the 4 pooled trials.

    Neutropenia

    < 1000/mm3

    46%

    49%

    < 500/mm3

    11%

    13%

    Anemia

    < 10 g/dL

    58%

    55%

    < 8 g/dL

    16%

    18%

    Thrombocytopenia

    < 150,000/mm3

    61%

    61%

    < 25,000/mm3

    1.4%

    4.2%

    Table 6: Non-Hematologic Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi’s Sarcoma

    Adverse Reactions

    Patients With Refractory or Intolerant
    AIDS-Related
    Kaposi’s Sarcoma
    (n=77*)

    Total Patients With
    AIDS-Related Kaposi’s Sarcoma
    (n=705**)

    Nausea

    18%

    17%

    Asthenia

    7%

    10%

    Fever

    8%

    9%

    Alopecia

    9%

    9%

    Alkaline Phosphatase Increase

    1.3%

    8%

    Vomiting

    8%

    8%

    Diarrhea

    5%

    8%

    Stomatitis

    5%

    7%

    Oral Moniliasis

    1.3%

    6%

    *This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.

    **This includes only subjects with AIDS-KS who had available adverse event data from the 4 pooled trials. 

    The following additional adverse reactions were observed in 705 patients with AIDS-related Kaposi’s sarcoma.

    Incidence 1% to 5%

    Body as a Whole: headache, back pain, infection, allergic reaction, chills.

    Cardiovascular: chest pain, hypotension, tachycardia.

    Cutaneous: herpes simplex, rash, itching.

    Digestive: mouth ulceration, anorexia, dysphagia.

    Metabolic and Nutritional: SGPT increase, weight loss, hyperbilirubinemia.

    Other: dyspnea, pneumonia, dizziness, somnolence.  

    Incidence Less Than 1%

    Body As A Whole: sepsis, moniliasis, cryptococcosis.

    Cardiovascular: thrombophlebitis, cardiomyopathy, palpitation, bundle branch block, congestive heart failure, heart arrest, thrombosis, ventricular arrhythmia.

    Digestive: hepatitis.

    Metabolic and Nutritional Disorders: dehydration.

    Respiratory: cough increase, pharyngitis.

    Skin and Appendages: maculopapular rash, herpes zoster.

    Special Senses: taste perversion, conjunctivitis. 

    Patients With Multiple Myeloma

    The safety data described are from 318 patients treated with doxorubicin hydrochloride liposome injection (30 mg/m2) administered on day 4 following bortezomib (1.3 mg/m2 i.v. bolus on days 1, 4, 8 and 11) every 3 weeks, in a randomized, open-label, multicenter study (Trial 6). In this trial, patients in the doxorubicin hydrochloride liposome injection + bortezomib combination group were treated for a median number of 4.5 months (range 21 days to 13.5 months). The population was 28 to 85 years of age (median age 61), 58% male, 90% Caucasian, 6% Black, and 4% Asian and Other. Table 7 lists adverse reactions reported in 10% or more of patients treated with doxorubicin hydrochloride liposome injection in combination with bortezomib for multiple myeloma. 

    Table 7: Frequency of Treatment-Emergent Adverse Reactions Reported in ≥10% Patients Treated for Multiple Myeloma With Doxorubicin Hydrochloride Liposome Injection in Combination With Bortezomib

     Adverse Reaction

    Doxorubicin Hydrochloride Liposome
    Injection + bortezomib
    (n=318)

    Bortezomib
    (n=318)

     

    Any (%)

    Grade 3-4

    Any (%)

    Grade 3-4

    Blood and lymphatic system disorders

    Neutropenia

    36

    32

    22

    16

    Thrombocytopenia

    33

    24

    28

    17

    Anemia

    25

    9

    21

    9

    General disorders and administration site conditions

     

     

     

     

    Fatigue

    36

    7

    28

    3

    Pyrexia

    31

    1

    22

    1

    Asthenia

    22

    6

    18

    4

    Gastrointestinal disorders

     

     

     

     

    Nausea

    48

    3

    40

    1

    Diarrhea

    46

    7

    39

    5

    Vomiting

    32

    4

    22

    1

    Constipation

    31

    1

    31

    1

    Mucositis/Stomatitis

    20

    2

    5

    <1

    Abdominal pain

    11

    1

    8

    1

    Infections and infestations

     

     

     

     

    Herpes zoster

    11

    2

    9

    2

    Herpes simplex

    10

    0

    6

    1

    Investigations

     

     

     

     

    Weight decreased

    12

    0

    4

    0

    Metabolism and Nutritional disorders

     

     

     

     

    Anorexia

    19

    2

    14

    <1

    Nervous system disorders

     

     

     

     

    Peripheral Neuropathy1

    42

    7

    45

    11

    Neuralgia

    17

    3

    20

    4

    Paresthesia/dysesthesia

    13

    <1

    10

    0

    Respiratory, thoracic and mediastinal disorders

     

     

     

     

    Cough

    18

    0

    12

    0

    Skin and subcutaneous tissue disorders

     

     

     

     

    Rash2 

    22

    1

    18

    1

    Hand-foot syndrome

    19

    6

    <1

    0

    1 Peripheral neuropathy includes the following adverse reactions: peripheral sensory neuropathy, neuropathy peripheral, polyneuropathy, peripheral motor neuropathy, and neuropathy NOS.

    2 Rash includes the following adverse reactions: rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash, and rash generalized.

    6.2 Postmarketing Experience

    The following additional adverse reactions have been identified during post approval use of doxorubicin hydrochloride liposome injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Musculoskeletal and Connective Tissue Disorders: muscle spasms

    Respiratory, Thoracic and Mediastinal Disorders: pulmonary embolism (in some cases fatal)

    Hematologic disorders: Secondary acute myelogenous leukemia

    Skin and subcutaneous tissue disorders: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichenoid keratosis.

    Secondary oral neoplasms:[see Warnings and Precautions (5.4)].

  • 7 DRUG INTERACTIONS

    No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on findings in animals and its mechanisms of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the use of doxorubicin hydrochloride liposome injection during the 1st trimester. In animal reproduction studies, doxorubicin hydrochloride liposome injection was embryotoxic in rats and abortifacient in rabbits following intravenous administration during organogenesis at doses approximately 0.12 times the recommended clinical dose [see Data].Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2nd and the 3rd trimesters. Advise pregnant women of the potential risk to a fetus.  

    The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.  

    Data

    Animal Data

    Doxorubicin hydrochloride liposome injection was embryotoxic at doses of 1 mg/kg/day in rats and was embryotoxic and abortifacient at 0.5 mg/kg/day in rabbits (both doses are about 0.12 times the recommended dose of 50 mg/m2 human dose on a mg/m2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced live litter sizes.  

    8.2 Lactation

    Risk Summary

    It is not known whether doxorubicin hydrochloride liposome injection is present in human milk. Because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from doxorubicin hydrochloride liposome injection, discontinue breastfeeding during treatment with doxorubicin hydrochloride liposome injection.

    8.3 Females and Males of Reproductive Potential

    Pregnancy Testing

    Verify the pregnancy status of females of reproductive potential prior to initiating doxorubicin hydrochloride liposome injection.

    Contraception

    Females

    Doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during and for 6 months after treatment with doxorubicin hydrochloride liposome injection.  

    Males

    Doxorubicin hydrochloride liposome injection may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and for 6 months after treatment with doxorubicin hydrochloride liposome injection [see Non-clinical Toxicology (13.1)].

    Infertility

    Females

    In females of reproductive potential, doxorubicin hydrochloride liposome injection may cause infertility and result in amenorrhea. Premature menopause can occur with doxorubicin hydrochloride. Recovery of menses and ovulation is related to age at treatment.  

    Males

    Doxorubicin hydrochloride liposome injection may result in oligospermia, azoospermia, and permanent loss of fertility. Sperm counts have been reported to return to normal levels in some men. This may occur several years after the end of therapy [see Nonclinical Toxicology (13.1)].

    8.4 Pediatric Use

    The safety and effectiveness of doxorubicin hydrochloride liposome injection in pediatric patients have not been established.

    8.5 Geriatric Use

    Clinical studies of doxorubicin hydrochloride liposome injection conducted in patients with either epithelial ovarian cancer (Trial 4) or with AIDS-related Kaposi’s sarcoma (Trial 5) did not contain sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects.

    In Trial 6, of 318 patients treated with doxorubicin hydrochloride liposome injection in combination with bortezomib for multiple myeloma, 37% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients. 

    8.6 Hepatic Impairment

    The pharmacokinetics of doxorubicin hydrochloride liposome injection has not been adequately evaluated in patients with hepatic impairment. Doxorubicin is eliminated in large part by the liver. Reduce doxorubicin hydrochloride liposome injection for serum bilirubin of 1.2 mg/dL or higher.  

  • 10 OVERDOSAGE

    Acute overdosage with doxorubicin hydrochloride causes increased risk of severe mucositis, leukopenia, and thrombocytopenia.

  • 11 DESCRIPTION

    The active ingredient in doxorubicin hydrochloride liposome injection is doxorubicin hydrochloride, USP, an anthracycline topoisomerase inhibitor, that is encapsulated in PEGYLATED liposomes for intravenous use.  

    The chemical name of doxorubicin hydrochloride, USP is (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride. The molecular formula is C27-H29-NO11HCl; its molecular weight is 579.99. The structural formula is:

    stru

    Doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion. Each vial contains 20 mg or 50 mg doxorubicin hydrochloride, USP at a concentration of 2 mg/mL (equivalent to 1.87 mg/mL of doxorubicin) and a pH of 6.5. The PEGYLATED liposome carriers are composed of cholesterol, 3.19 mg/mL; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg/mL; and N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg/mL. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine as a buffer; hydrochloric acid and/or sodium hydroxide for pH control; and sucrose to maintain isotonicity. Greater than 90% of the drug is encapsulated in the PEGYLATED liposomes. 

    MPEG-DSPE has the following structural formula:

    MPEG

    n=ca. 45

    HSPC has the following structural formula:

    HSPC

    m,n=14 or 16

    Representation of a PEGYLATED liposome:

    PEGLYATED
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The active ingredient of doxorubicin hydrochloride liposome injection is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.

    12.3 Pharmacokinetics

    The pharmacokinetic parameters for total doxorubicin following a single dose of doxorubicin hydrochloride liposome injection infused over 30 minutes are presented in Table 8.  

    Table 8: Pharmacokinetic Parameters of Total Doxorubicin from Doxorubicin Hydrochloride Liposome Injection in Patients With AIDS-Related Kaposi’s Sarcoma

     

    Dose

    Parameter (units)

    10 mg/m2

    20 mg/m2

    Peak Plasma Concentration (mcg/mL)

    4.12 ± 0.215

    8.34 ± 0.49

    Plasma Clearance (L/h/m2)

    0.056 ± 0.01

    0.041 ± 0.004

    Steady State Volume of Distribution (L/m2)

    2.83 ± 0.145

    2.72 ± 0.120

    AUC (mcg/mLh) 

    277 ± 32.9

    590 ± 58.7

    First Phase (λ1) Half-Life (h)

    4.7 ± 1.1

    5.2 ± 1.4

    Second Phase (λ1) Half-Life (h)

    52.3 ± 5.6

    55 ± 4.8

    N=23

    Mean ± Standard Error

    Doxorubicin hydrochloride liposome injection displayed linear pharmacokinetics over the range of 10 to 20 mg/m2. Relative to doxorubicin hydrochloride liposome injection doses at or below 20 mg/m2, the pharmacokinetics of total doxorubicin following a 50 mg/m2 doxorubicin hydrochloride liposome injection dose are nonlinear. At this dose, the elimination half-life of doxorubicin hydrochloride liposome injection is longer and the clearance lower compared to a 20 mg/m2 dose.  

    Distribution:

    Direct measurement of liposomal doxorubicin shows that at least 90% of the drug (the assay used cannot quantify less than 5 to 10% free doxorubicin) remains liposome-encapsulated during circulation.  

    In contrast to doxorubicin, which displays a large volume of distribution (range 700 to 1100 L/m2), the small steady state volume of distribution of liposomal doxorubicin suggests that doxorubicin hydrochloride liposome injection is largely confined to vascular fluid. Doxorubicin becomes available after the liposomes are extravasated. Plasma protein binding of doxorubicin hydrochloride liposome injection has not been determined; the plasma protein binding of doxorubicin is approximately 70%.  

    Metabolism:

    Doxorubicinol, the major metabolite of doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m2 doxorubicin hydrochloride liposome injection.

    Elimination:

    The plasma clearance of total doxorubicin from doxorubicin hydrochloride liposome injection was 0.041 L/h/m2 at a dose of 20 mg/m2. Following administration of doxorubicin, the plasma clearance of doxorubicin is 24 to 35 L/h/m2 .

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

    Mutagenicity or carcinogenicity studies have not been conducted with doxorubicin hydrochloride liposome injection, however doxorubicin was shown to be mutagenic in the in vitro Ames assay, and clastogenic in multiple in vitro assays (CHO cell, V79 hamster cell, human lymphoblast, and SCE assays) and the in vivo mouse micronucleus assay. The possible adverse effects on fertility in animals have not been adequately evaluated. Doxorubicin hydrochloride liposome injection resulted in mild to moderate ovarian and testicular atrophy in mice after administration of a single dose of 36 mg/kg (about 2 times the 50 mg/m2 human dose on a mg/m2 basis). Decreased testicular weights and hypospermia were observed in rats after repeat doses ≥ 0.25 mg/kg/day (about 0.03 times the 50 mg/m2 human dose on a mg/m2 basis), and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (about 0.4 times the 50 mg/m2 human dose on a mg/m2 basis).

  • 14 CLINICAL STUDIES

    14.1 Ovarian Cancer

    Doxorubicin hydrochloride liposome injection was studied in three open-label, single-arm, clinical studies of 176 patients with metastatic ovarian cancer (Trials 1, 2, and 3). One hundred forty-five of these patients were refractory to both paclitaxel-and platinum-based chemotherapy regimens, defined as disease progression while on treatment or relapse within 6 months of completing treatment. Patients received doxorubicin hydrochloride liposome injection at 50 mg/m2 every 3 or 4 weeks for 3 to 6+ cycles in the absence of dose-limiting toxicity or disease progression.

    The median age at diagnosis ranged from 52 to 64 years in the 3 studies, and the range was 22 to 85. Most patients had International Federation of Obstetricians and Gynecologists (FIGO) stage III or IV disease (ranging from 83% to 93%). Approximately one third of the patients had three or more prior lines of therapy (ranging from 22% to 33%).

    The primary outcome measure was confirmed response rate based on Southwestern Oncology Group (SWOG) criteria for patients refractory to both paclitaxel-and a platinum-containing regimen. Secondary efficacy parameters were time to response, duration of response, and time to progression. 

    The response rates for the individual single arm trials are given in Table 9 below. 

    Table 9: Response Rates in Patients With Refractory Ovarian Cancer From Single Arm Ovarian Cancer Trials

     

    Trial 1
    (U.S.)
    N=27

    Trial 2
    (U.S.)
    N=82

    Trial 3
    (non-U.S.)
    N=36

    Response Rate

    22.2%

    17.1%

    0%

    95% Confidence Interval

    8.6% -42.3%

    9.7% -27%

    0% -9.7%

    In a pooled analysis of Trials 1 to 3, the response rate for all patients refractory to paclitaxel and platinum agents was 13.8% (95% CI 8.1% to 19.3%). The median time to progression was 15.9 weeks, the median time to response was 17.6 weeks, and the duration of response was 39.4 weeks.

    In Trial 4, a randomized, multicenter, open-label, trial in 474 patients with epithelial ovarian cancer after platinum-based chemotherapy, patients were randomized to receive either doxorubicin hydrochloride liposome injection 50 mg/m2 every 4 weeks (n=239) or topotecan 1.5 mg/m2 daily for 5 consecutive days every 3 weeks (n=235). Patients were stratified according to platinum sensitivity (response to initial platinum-based therapy and a progression-free interval of greater than 6 months off treatment) and the presence of bulky disease (tumor mass greater than 5 cm in size). The primary outcome measure was time to progression (TTP). Other endpoints included overall survival and objective response rate.

    Of the 474 patients, the median age at diagnosis was 60 years (range 25 to 87), 90% were FIGO stage III and IV; 46% were platinum sensitive; and 45% had bulky disease.  There was no statistically significant difference in TTP between the two arms. Results are provided in Table 10.

    Table 10: Results of Efficacy Analyses1

     

    Protocol Defined ITT Population

     

    Doxorubicin Hydrochloride
    Liposome Injection
    (n=239)

     

    Topotecan(n=235)

    TTP (Protocol Specified Primary Endpoint)
    Median (Months)2
    p-value3 

    Hazard Ratio4 

    4.1

    0.62
    0.96

    4.2

    95% CI for Hazard Ratio

     

    (0.76, 1.20)

     

    Overall Survival

     

     

     

    Median (Months)2

    p-value5 

    Hazard Ratio4

    14.4

    0.05 

    0.82

    13.7

    95% CI for Hazard Ratio

     

    (0.68, 1)

     

    Response Rate

     

     

     

    Overall Response n (%)

    47 (19.7)

     

    40 (17)

    Complete Response n (%)

    9 (3.8)

     

    11 (4.7)

    Partial Response n (%)

    38 (15.9)

     

    29 (12.3)

    Median Duration of Response (Months)2

    6.9

     

    5.9

     1 Analysis based on investigators’ strata for protocol defined ITT population.
    2 Kaplan-Meier estimates.
    3 p-value is based on the stratified log-rank test.
    4Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for doxorubicin hydrochloride liposome injection.
    5 p-value not adjusted for multiple comparisons. 

    14.2 AIDS-Related Kaposi’s Sarcoma

    Doxorubicin hydrochloride liposome injection was studied in an open-label, single-arm, multicenter study at a dose of 20 mg/m2 every 3 weeks, until disease progression or unacceptable toxicity (Trial 5).  

    Data is described for a cohort of 77 patients retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least two cycles of a regimen containing at least two of three treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. Forty-nine of the 77 (64%) patients had received prior doxorubicin hydrochloride.  

    The median time on study was 5.1 months (range 1 day to 15 months). The median cumulative dose of doxorubicin hydrochloride liposome injection was 154 mg/m2 (range 20 to 620 mg/m2). Among the 77 patients, mean age was 38 years (range 24 to 54); 87% were Caucasian, 5% Hispanic, 4% Black, and 4% Asian/Other/Unknown; median CD4 count was 10 cells/mm3; ACTG staging criteria were 78% poor risk for tumor burden, 96% poor risk for immune system, and 58% poor risk for systemic illness at baseline; and mean Karnofsky status score was 74%. All patients had cutaneous or subcutaneous lesions, 40% also had oral lesions, 26% pulmonary lesions, and 14% had lesions of the stomach/intestine. 

    Two analyses of tumor response were used: one based on investigator assessment of changes in lesions based on modified ACTG criteria (partial response defined as no new lesions, sites of disease, or worsening edema; flattening of ≥50% of previously raised lesions or area of indicator lesions decreasing by ≥50%; and response lasting at least 21 days with no prior progression), and one based on changes in up to five prospectively indentified representative indicator lesions (partial response defined as flattening of ≥50% of previously raised indicator lesions, or >50% decrease in the area of indicator lesions and lasting at least 21 days with no prior progression). Of the 77 patients, 34 were evaluable for investigator assessment and 42 were evaluable for indicator lesion assessment; analyses of tumor responses are shown in Table 11.

    Table 11: Response in Patients with Refractory1 AIDS-Related Kaposi’s Sarcoma

    Investigator Assessment

    All Evaluable Patients
    (n=34)

    Evaluable Patients Who
    Received Prior
    Doxorubicin
    (n=20)

    Response2

    Partial (PR)

    27%

    30%

    Stable

    29%

    40%

    Progression

    44%

    30%

    Duration of PR (Days)

    Median

    73

    89

    Range

    42+ – 210+

    42+ – 210+

    Time to PR (Days)

    Median

    43

    53

    Range

    15 – 133

    15 – 109

    Indicator Lesion
    Assessment

    All Evaluable Patients
    (n=42)

    Evaluable Patients Who Received
    Prior Doxorubicin
    (n=23)

    Response2

    Partial (PR)

    48%

    52%

    Stable

    26%

    30%

    Progression

    26%

    17%

    Duration of PR (Days)

    Median

    71

    79

    Range

    22+ – 210+

    35 – 210+

    Time to PR (Days)

    Median

    22

    48

    Range

    15 – 109

    15 – 109

    1 Patients with disease that progressed on prior combination chemotherapy or who were intolerant to such therapy.

    2 There were no complete responses in this population. 

    Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent doxorubicin hydrochloride liposome injection and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial, 7 of 17 (40%) patients had a durable response (median duration not reached but was longer than 11.6 months). In the second trial, 4 of 11 patients (40%) on a stable antiretroviral therapy demonstrated durable responses.

    14.3 Multiple Myeloma

    The efficacy of doxorubicin hydrochloride liposome injection in combination with bortezomib was evaluated in Trial 6, a randomized, open-label, international, multicenter study in 646 patients who had not previously received bortezomib and whose disease progressed during or after at least one prior therapy. Patients were randomized (1:1) to receive either doxorubicin hydrochloride liposome injection (30 mg/m2) administered IV on day 4 following bortezomib (1.3 mg/m2 IV on days 1, 4, 8 and 11) or bortezomib alone every 3 weeks for up to 8 cycles or until disease progression or unacceptable toxicity. Patients who maintained a response were allowed to receive further treatment. The median number of cycles in each treatment arm was 5 (range 1 to 18). 

    The baseline demographics and clinical characteristics of the patients with multiple myeloma were similar between treatment arms (Table 12).

    Table 12: Summary of Baseline Patient and Disease Characteristics

    Patient Characteristics

    Doxorubicin Hydrochloride Liposome
    Injection+bortezomib
    n=324

    bortezomib
    N=322

    Median age in years (range)

    61 (28, 85)

    62 (34, 88)

    % Male/female

    58 / 42

    54 / 46

    % Caucasian/Black/other

    90 / 6/ 4

    94 / 4 / 2

    Disease Characteristics

     

    % with IgG/IgA/Light chain

    57 / 27 / 12

    62 / 24 /11

    % β2 -microglobulin group

     

    ≤2.5 mg/L

    14

    14

    >2.5 mg/L and ≤5.5 mg/L

    56

    55

    >5.5 mg/L

    30

    31

    Serum M-protein (g/dL): Median (Range)

    2.5 (0 to10)

    2.7 (0 to 10)

    Urine M-protein (mg/24 hours): Median (Range)

    107 (0 to 24883)

    66 (0 to 39657)

    Median Months Since Diagnosis

    35.2

    37.5

    % Prior Therapy

     

     

    One

    34

    34

    More than one

    66

    66

    Prior Systemic Therapies for Multiple Myeloma

     

     

    Corticosteroid (%)

    99

    >99

    Anthracyclines

    68

    67

    Alkylating agent (%)

    92

    90

    Thalidomide/lenalidomide (%)

    40

    43

    Stem cell transplantation (%)

    57

    54

    The primary outcome measure was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease. The combination arm demonstrated significant improvement in TTP. As the prespecified primary objective was achieved at the interim analysis, patients in the bortezomib monotherapy group were then allowed to receive the doxorubicin hydrochloride liposome injection + bortezomib combination. Efficacy results are as shown in Table 13 and Figure 1.

    Table 13: Efficacy of Doxorubicin Hydrochloride Liposome Injection in Combination With Bortezomib in the Treatment of Patients With Multiple Myeloma

    Endpoint

    Doxorubicin Hydrochloride
    Liposome Injection + bortezomib
    n=324

     

    Bortezomib
    n=322

    Time to Progression1 

    Progression or death due to progression (n)

     

    99

     

     

    150

    Censored (n)

    225

     

    172

    Median in days (months)

    282 (9.3)

     

    197 (6.5)

    95% CI

    250;338

     

    170;217

    Hazard ratio2 

    (95% CI)

    p-value3

     

    0.55

    (0.43, 0.71)

    <0.001

     

    Response (n)4

    303

     

    310

    % Complete Response (CR)

    5

     

    3

    % Partial Response (PR)

    43

     

    40

    % CR + PR

    48

     

    43

    p-value5

     

    0.25

     

    Median Duration of Response (months) (95% CI)

    10.2

    (10.2;12.9)

     

    7

    (5.9;8.3)

    1 Kaplan Meier estimate. 

    2 Hazard ratio based on stratified Cox proportional hazards regression. A hazard ratio < 1 indicates an advantage for doxorubicin hydrochloride liposome injection+bortezomib. 

    3 Stratified log-rank test.

    4 RR as per EBMT criteria.

    5 Cochran-Mantel-Haenszel test adjusted for the stratification factors.

    Figure 1-Time to Progression Kaplan-Meier Curve

    graph

    At the final analysis of survival, 78% of subjects in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had died after a median follow up of 8.6 years. The median survival was 33 months in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 31 months in the bortezomib monotherapy group. There was no difference observed in overall survival at the final analysis [HR for doxorubicin hydrochloride liposome injection + bortezomib vs. bortezomib= 0.96 (95% CI 0.80, 1.14)].

    Seventy-eight percent of subjects in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had received subsequent therapy.

  • 15 REFERENCES

    1. “Hazardous Drugs”, OSHA, http://www.osha.gov/SLTC/hazardousdrugs/index.html

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single-dose vials.  

    Each 10-mL vial contains 20 mg doxorubicin hydrochloride, USP at a concentration of 2 mg/mL.  

    Each 30-mL vial contains 50 mg doxorubicin hydrochloride, USP at a concentration of 2 mg/mL. 

    The following individually cartoned vials are available: 

    Table 14

    mg in vial

    fill volume

    vial size

    NDC #s

    20 mg vial

    10-mL

    10-mL

    68001-345-36

    50 mg vial

    25-mL

    30-mL

    68001-345-26

    Refrigerate unopened vials of doxorubicin hydrochloride liposome injection at 2° C -8°C (36° F - 46°F). Do not freeze. Discard unused portion  

    Doxorubicin hydrochloride liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 

  • 17 PATIENT COUNSELING INFORMATION

    Cardiomyopathy

    Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.1)].  

    Infusion-Related Reactions

    Advise patients about the symptoms of infusion-related reactions and to seek immediate medical attention if they develop any of these symptoms [see Warnings and Precautions (5.2)].  

    Myelosuppression

    Advise patients to contact their healthcare provider for a new onset fever or symptoms of infection.  

    Hand-Foot Syndrome

    Advise patients to notify their healthcare provider if they experience tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of their hands or soles of their feet (symptoms of Hand-Foot Syndrome) [see Warnings and Precautions (5.3)]. 

    Stomatitis

    Advise patients to notify their healthcare provider if they develop painful redness, swelling, or sores in the mouth (symptoms of stomatitis).

    Embryo-Fetal Toxicity

    Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1)].  

    Advise females and males of reproductive potential to use effective contraception during and for 6 months following treatment with doxorubicin hydrochloride liposome injection [see Use in Specific Populations (8.3)].  

    Lactation

    Advise females not to breastfeed during treatment with doxorubicin hydrochloride liposome injection [see Use in Specific Populations (8.2)].

    Infertility

    Advise females and males of reproductive potential that doxorubicin hydrochloride liposome injection may cause temporary or permanent infertility [see Use in Specific Populations (8.3)].  

    Discoloration of Urine and Body Fluids

    Inform patients that following doxorubicin hydrochloride liposome injection administration, a reddish-orange color to the urine and other body fluids may be observed. This nontoxic reaction is due to the color of the product and will dissipate as the drug is eliminated from the body.

    Rx Only 

    Mfd. By: Natco Pharma Ltd

    Kothur – 509 228 INDIA.

    For BluePoint Laboratories

    Issued: 12/19  

  • Package/Label Display Panel

    Doxorubicin Hydrochloride Liposome Injection

    20mg/10mL (2mg/mL)

    NDC: 68001-345-36

    Single-Dose Vial Label

    Doxorubicin HCl Liposome Inj 20mg_10mL Label
  • Package/Label Display Panel

    Doxorubicin Hydrochloride Liposome Injection

    20mg/10mL (2mg/mL)

    NDC: 68001-345-36

    Single-Dose Vial Carton

    Doxorubicin HCl 20mg/10mL Carton Rev 1219
  • Package/Label Display Panel

    Doxorubicin Hydrochloride Liposome Injection

    50mg/25mL (2mg/mL)

    NDC: 68001-345-26

    Single-Dose Vial Label

    Doxorubicin HCl Liposome Inj 50mg_25mL Label
  • Package/Label Display Panel

    Doxorubicin Hydrochloride Liposome Injection

    50mg/25mL (2mg/mL)

    NDC: 68001-345-26

    Single-Dose Vial Carton

    Doxorubicin HCl 50mg/25mL Carton Rev 1219
  • INGREDIENTS AND APPEARANCE
    DOXORUBICIN HYDROCHLORIDE 
    doxorubicin hydrochloride injectable, liposomal
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 68001-345
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Doxorubicin Hydrochloride (UNII: 82F2G7BL4E) (Doxorubicin - UNII:80168379AG) Doxorubicin Hydrochloride2 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Ammonium Sulfate (UNII: SU46BAM238)  
    Histidine (UNII: 4QD397987E)  
    Hydrochloric Acid (UNII: QTT17582CB)  
    Sodium Hydroxide (UNII: 55X04QC32I)  
    Sucrose (UNII: C151H8M554)  
    Cholesterol (UNII: 97C5T2UQ7J)  
    Hydrogenated Soybean Lecithin (UNII: H1109Z9J4N)  
    SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE (UNII: 3L6NN8ZZKU)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 68001-345-361 in 1 CARTON02/16/2018
    110 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    2NDC: 68001-345-261 in 1 CARTON02/16/2018
    225 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20865702/16/2018
    Labeler - BluePoint Laboratories (985523874)
    Registrant - Dr. Reddy’s Laboratories Limited (650562841)
    Establishment
    NameAddressID/FEIBusiness Operations
    Natco Pharma Ltd918588174ANALYSIS(68001-345) , MANUFACTURE(68001-345)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.